It works by mimicking glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut, which regulates appetite, promotes satiety, and stabilizes blood sugar levels
Selective MC1R agonist primary receptor target MC1R with secondary activity at MC3R, MC4R, MC5R Two targeted modifications vs native -MSH Nle and D-Phe enhance metabolic stability in experimental systems Linear 13 amino acid structure distinct from cyclic MT-2 (Melanotan II) with different receptor selectivity profile Activates cAMP/PKA signaling cascade via MC1R in cell-based research systems Studied extensively in melanogenesis, melanocortin receptor pharmacology, and comparative ligand selectivity research FDA-approved pharmaceutical equivalent (Scenesse/Afamelanotide) provides extensive published clinical literature for reference Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background MT-1 (Afamelanotide) was developed in the 1980s at the University of Arizona by Mac Hadley and Victor Hruby as part of a program investigating synthetic -MSH analogs for melanocortin receptor research
Practice Good Oral Hygiene: Brush your teeth twice a day, floss daily, and consider using a tongue scraper to remove bacteria that can contribute to bad tastes
NAD+ regulates nucleotide metabolism and genomic DNA replication
GLP-1/GIP Dual Agonists: A next-generation medication that targets multiple pathways to accelerate fat loss, control blood sugar, and enhance satiety often resulting in even faster, more powerful results
Aim for 80+ ounces of water daily
.png)
